Almanac Health Lands $10M to Build AI Doctors Can Actually Trust

BOSTON, MA – April 23, 2026 – In a healthcare landscape saturated with promises of AI-driven transformation, one company is betting that trust, not just technology, is the key to the future. Almanac Health, a clinical AI startup, announced today it has raised $10 million in a seed round led by F-Prime, bringing its total funding to nearly $12 million. The company aims to tackle one of the biggest hurdles for AI in medicine: its credibility crisis.

With participation from General Catalyst and Lightspeed Venture Partners, the new capital will accelerate Almanac Health’s mission to equip clinicians with a safe, evidence-grounded AI platform. The system is designed to provide specialist-grade knowledge directly within hospital workflows, all while being rigorously validated and free from the influence of pharmaceutical advertising. This approach stands in stark contrast to the wave of unverified AI tools that have left many physicians skeptical.

Building a Foundation of Trust in Clinical AI

The rapid proliferation of generative AI has created both excitement and apprehension in the medical community. While the potential to streamline workflows and improve diagnostics is immense, the risk of AI "hallucinations"—where a model generates plausible but factually incorrect information—poses a direct threat to patient safety. This has led to a significant "trust gap," where clinicians are hesitant to adopt tools that cannot guarantee reliability and accuracy.

Almanac Health was founded to bridge this gap. The company’s entire philosophy is built on a foundation of evidence and integrity.

“There is no shortage of technologies promising to transform medicine. But few are grounded in real evidence, built with integrity and deserving of trust from the people and organizations using them,” said Cyril Zakka, MD, founder and CEO of Almanac Health. “Almanac Health’s goal is to build clinical AI held to that standard. Validated through research, with incentives aligned with clinicians and patients. We’re focused on getting that right.”

This commitment extends beyond just algorithmic accuracy. The platform is designed for governance by institutional controls, meaning hospitals can manage how the AI is used, and its promise to remain free from pharmaceutical advertising ensures that clinical recommendations are not biased by commercial interests. The system is currently undergoing rigorous clinical validation in academic medical center settings, a crucial step that many competitors in the bustling AI space have yet to undertake.

The Architect of Accuracy: RAG at the Core

At the heart of Almanac Health’s promise of reliability is a specific technological approach known as Retrieval-Augmented Generation (RAG). Dr. Zakka is a recognized pioneer in this area, having authored one of NEJM AI's most-cited papers on applying RAG to clinical medicine during his research at Stanford.

Unlike standard large language models that generate responses based solely on their vast, static training data, a RAG system functions more like a diligent research assistant. When posed with a clinical question, the AI first retrieves relevant, up-to-date information from a curated, trusted knowledge base—such as the latest peer-reviewed studies, established medical textbooks, and institutional clinical guidelines. It then uses this retrieved evidence to "augment" or inform its generated response.

This two-step process is the key to preventing hallucinations. By grounding every piece of output in verifiable source material, the AI is forced to "show its work." This not only ensures the information is accurate and current but also provides a layer of transparency that is critical for clinical adoption. Doctors can, in theory, review the same evidence the AI used to reach its conclusion, fostering a collaborative relationship between the clinician and the technology rather than demanding blind faith. This model directly addresses a major limitation of many AI systems, moving them from opaque "black boxes" to transparent decision-support partners.

Navigating a Competitive Landscape

Almanac Health enters a fiercely competitive market. The clinical AI space is crowded with a diverse array of players, from established electronic health record (EHR) giants like Epic and Oracle integrating their own AI features, to specialized startups like Glass Health and Abridge focusing on documentation and decision support. Tech behemoths like Google, Microsoft, and Amazon are also making significant inroads with their own healthcare-focused AI platforms.

The market, projected to be worth over $15 billion by the next decade, is dominated by tools that promise to reduce administrative burden and streamline workflows. However, many of these solutions are still grappling with issues of accuracy, EHR integration, and, most importantly, clinician trust.

This is where Almanac Health aims to carve out its niche. Instead of competing solely on features, the company is differentiating itself on principle. By prioritizing rigorous validation before widespread deployment and aligning its business model with patient and clinician interests, it is positioning itself as the responsible choice in a field prone to hype cycles. The platform's design to integrate seamlessly with existing EHR systems is also a critical factor, as it aims to enhance, not disrupt, the established workflows of busy clinicians.

Why Top VCs Are Betting on Evidence-Based AI

The decision by F-Prime, General Catalyst, and Lightspeed to back Almanac Health is a telling indicator of a broader shift in the health tech investment landscape. After years of funding rapid growth, venture capitalists are now placing a premium on safety, reliability, and long-term viability, especially in a high-stakes field like medicine.

Investors see a clear need for a new generation of AI tools built on a foundation of scientific rigor. The backing of Dr. Zakka, who possesses a rare blend of clinical experience and deep technical expertise in AI, was a key factor.

“Cyril is one of the rare founders who has both the clinical training and the technical depth to build AI that clinicians will actually trust as well as the discipline to validate it before deploying it,” said Carl Byers, Partner at F-Prime. “Almanac Health represents what we believe the next generation of healthcare AI should look like: grounded in research, governed by institutions, and built with incentives that put clinicians and patients first.”

This sentiment was echoed by General Catalyst, which previously led the company’s pre-seed round. “We believe the next generation of healthcare infrastructure will be defined by how effectively it translates frontier intelligence into everyday clinical decisions,” said Alexandre Momeni, Partner at General Catalyst. “Almanac is doing exactly that: building a physician-centric platform that brings trusted, evidence-based intelligence into the workflow.”

The $10 million in funding will be used to expand the company’s team across clinical medicine, AI research, and health systems infrastructure. A significant portion will also be dedicated to advancing research and development, with a continued focus on privacy, reliability, and the rigorous evaluation that forms the core of the company's identity. As Almanac Health moves forward, its success could provide a new blueprint for how to responsibly innovate at the intersection of artificial intelligence and human health.